Background and objectives: The current standard of treatment for malignant peritoneal mesothelioma (MPM) is cytoreductive surgery (CRS) plus perioperative intraperitoneal or systemic chemotherapy (comprehensive treatment), The present study was performed to clarify the prognostic factors of PMP after comprehensive treatment. Methods: Among 63 patients with MPM, male and female patients were 34 and 29. CRS was performed in 47 patients and complete cytoreduction (CC-0) was performed in14 (22%) patients. Mean numbers of resected peritoneal sectors and organs were 5.2 (1-13), and 2.9 (0-9), respectively. Hyperthermic intraperitoneal chemoperfusion (HIPEC) was performed in 27 patients. Grade 1/2, Grade 3, and Grade 4 complications were experienced in 5, 6, and 3 patients, respectively. One patient died of sepsis, and the mortality rate was 2.3%. Independent prognostic factors for favorable prognosis were performance of HIPEC, peritoneal cancer index (PCI) score <12, no distant metastasis and histologic epithelial type. Relative risk of no HIPEC, PCI score >13, presence of distant metastasis and non epithelial type were 7.69, 22.1,3.6 and 3.9, respectively. Conclusions: Risk factors for death after comprehensive treatment were no HIPEC, PCI score >13, and non epithelial type. However, only11(17%) patients showed PCI score <12. Accordingly, PCI score should be reduced <12 before CRS by neoadjuvant chemotherapy. ^g>Peritoneal mesothelioma, HIPEC, Peritonectomy, cytoreductive surgery
展开▼
